Literature DB >> 22520949

Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.

Justin M M Cates1, Jennifer O Black, Doha M Itani, John H Fasig, Vicki L Keedy, Kenneth R Hande, Brent W Whited, Kelly C Homlar, Jennifer L Halpern, Ginger E Holt, Herbert S Schwartz, Cheryl M Coffin.   

Abstract

Despite reports of receptor tyrosine kinase activation in desmoid-type fibromatosis, therapeutic benefits of kinase inhibitor therapy are unpredictable. Variability in signal transduction or cellular kinases heretofore unevaluated in desmoid tumors may be responsible for these inconsistent responses. In either case, a better understanding of growth regulatory signaling pathways is necessary to assess the theoretical potential of inhibitor therapy. Immunohistochemical analysis of tyrosine kinases and activated isoforms of downstream signal transduction proteins was performed on a tissue microarray containing 27 cases of desmoid-type fibromatosis and 14 samples of scar; 6 whole sections of normal fibrous tissue were studied for comparison. Platelet-derived growth factor receptor, β type, and focal adhesion kinase 1 were expressed in all desmoid tumors and healing scars but only 80% and 50% of nonproliferative fibrous tissue samples, respectively. Hepatocyte growth factor receptor was detected in 89% of desmoids and all scars tested, but not in any of the fibrous tissue samples. Epidermal growth factor receptor was detected in only 12% of desmoids and not in scar or fibrous tissue. Mast/stem cell growth factor receptor, receptor tyrosine-protein kinase erbB-2, and phosphorylated insulin-like growth factor 1 receptor/insulin receptor were negative in all study cases. Variable levels of phosphorylated downstream signal transduction molecules RAC-α/β/γ serine/threonine-protein kinase, mitogen-activated protein kinase, and signal transducer and activator of transcription-3 were observed in desmoids (58%, 62%, and 67%), scar tissues (100%, 86%, and 86%), and fibrous tissue (33%, 17%, and 17%). These results indicate that tyrosine kinase signaling is active in both fibromatosis and healing scar, but not in most nonproliferating fibrous tissues. Although platelet-derived growth factor receptor, β type, is expressed ubiquitously in desmoids, the kinases driving cell proliferation in desmoids remain unresolved.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22520949      PMCID: PMC4278590          DOI: 10.1016/j.humpath.2011.12.021

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  34 in total

Review 1.  Myofibroblasts. I. Paracrine cells important in health and disease.

Authors:  D W Powell; R C Mifflin; J D Valentich; S E Crowe; J I Saada; A B West
Journal:  Am J Physiol       Date:  1999-07

Review 2.  Regulation of PDGF and its receptors in fibrotic diseases.

Authors:  James C Bonner
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

Review 3.  Convergence of Wnt, beta-catenin, and cadherin pathways.

Authors:  W James Nelson; Roel Nusse
Journal:  Science       Date:  2004-03-05       Impact factor: 47.728

4.  Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors.

Authors:  Nancy L Cho; Adelaide M Carothers; Hira Rizvi; Rian M Hasson; Mark Redston; Monica M Bertagnolli
Journal:  J Surg Res       Date:  2010-11-26       Impact factor: 2.192

5.  Cytokines associated with the pathophysiology of aggressive fibromatosis.

Authors:  B G Mills; A Frausto; E Brien
Journal:  J Orthop Res       Date:  2000-07       Impact factor: 3.494

6.  Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.

Authors:  Joseph Mace; J Sybil Biermann; Vernon Sondak; Cornelius McGinn; Curtis Hayes; Dafydd Thomas; Laurence Baker
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.860

7.  Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity.

Authors:  Lan Zhou; Naili An; Rex C Haydon; Qixin Zhou; Hongwei Cheng; Ying Peng; Wei Jiang; Hue H Luu; Pantila Vanichakarn; Jan Paul Szatkowski; Jae Yoon Park; Benjamin Breyer; Tong-Chuan He
Journal:  Cancer Lett       Date:  2003-04-25       Impact factor: 8.679

8.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

Authors:  Craig E Daniels; Mark C Wilkes; Maryanne Edens; Ted J Kottom; Stephen J Murphy; Andrew H Limper; Edward B Leof
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

9.  Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase.

Authors:  Victor J Thannickal; Daniel Y Lee; Eric S White; Zongbin Cui; Jose M Larios; Raquel Chacon; Jeffrey C Horowitz; Regina M Day; Peedikayil E Thomas
Journal:  J Biol Chem       Date:  2003-01-16       Impact factor: 5.157

10.  Identification of IGFBP-6 as a significantly downregulated gene by beta-catenin in desmoid tumors.

Authors:  Hannelore Denys; Ali Jadidizadeh; Saeid Amini Nik; Kim Van Dam; Stein Aerts; Benjamin A Alman; Jean-Jacques Cassiman; Sabine Tejpar
Journal:  Oncogene       Date:  2004-01-22       Impact factor: 9.867

View more
  1 in total

Review 1.  Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.

Authors:  Thomas D McLean; Serena Duchi; Claudia Di Bella
Journal:  Target Oncol       Date:  2022-04-21       Impact factor: 4.864

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.